NEW YORK, June 28 Reportlinker.com announces that a new market research report is available in its catalogue:
http://www.reportlinker.com/p0197199/Global-Huntingtons-Disease-Therapeutics-industry.html
Advertisement
This report analyzes the Global market for Huntington's Disease Therapeutics in US$ Million. Annual estimates and forecasts are provided for the period 2009 through 2015. The report profiles 37 companies including Alnylam Pharmaceuticals, Inc., Amarin Corporation, Plc, Avicena Group, Inc., Biovail Corporation, Ceregene, Inc., Cortex Pharmaceuticals, Inc., H. Lundbeck A/S, Intellect Neurosciences Incorporation, Medivation, Inc., NeuroSearch A/S, Prana Biotechnology Limited, Raptor Pharmaceuticals Corp., Targeted Genetics Corporation, Trophos SA, and Vertex Pharmaceuticals Incorporated. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.
Advertisement
HUNTINGTON'S DISEASE THERAPEUTICS MCP-6280
A GLOBAL MARKET REPORT
CONTENTS
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation & Reporting Level I-3
Quantitative Techniques & Analytics I-3
Product Definitions and Scope of Study I-3
II. EXECUTIVE SUMMARY
1. INDUSTRY OVERVIEW II-1
A Prelude II-1
Market Opportunity II-1
Unmet Clinical Needs to Foster R&D Engine II-2
Support Organizations Play An Instrumental Role II-2
Improved Diagnostics Boosts HD Management II-2
Competition in the Global HD Market is Nonexistent II-3
Reimbursement Issues for HD II-3
Effectiveness of Current HD Management Strategies II-3
Affordability of Xenazine Will Be Key for Sustained Uptake II-4
Off-Label Prescriptions II-4
Select Off-Label Drugs Prescribed for Huntington's Disease II-5
Rising Interest in HD Drugs Development II-5
Drug Development Pipeline Reveals A Promising Picture II-6
Public-Private Partnerships: A Shot in the Arm II-6
Dimebon(TM) Candidacy As a Potent HD Drug Appear Doubtful II-6
Drugs in Pipeline II-6
HD-02 II-6
Huntexil(TM) (Pridopidine or ACR16) II-7
OXIGON(TM) II-8
AMR101 (Miraxion(TM)) II-8
DR Cysteamine II-9
PBT2 II-10
Select Pipeline Drugs for Treatment of Huntington's Disease
As of 2009 II-10
Promising Research Breakthroughs II-11
Lundbeck Announces Successful Open-Label Results for Xenazine II-11
UCLA Scientists Identify Molecular Switch to Check
Huntington's Disease in Mice II-11
Molecular Switch Capable of Blocking Huntington's Disease
Identified II-11
Novel Drug Targets Recognized for Huntington's Disease II-12
First Transgenic Monkey Model of Huntington's Disease Developed II-12
Other Novel Approaches for HD Treatment II-13
CERE-120 II-13
Cellular Delivery of Neurotropic Agents II-13
Cogane II-13
COPREXA II-14
Histone Deacetylases (HDAC) II-14
Melatonin, Coenzyme Q-Free Radical Scavengers II-14
Minocycline - Caspase Inhibition II-14
RNAi - RNA Interference II-15
Small Molecule Inhibitor of Polyglutamine Interaction II-15
TELOMICS(TM) II-15
2. AN OVERVIEW OF HUNTINGTON'S DISEASE II-16
Introduction II-16
Historical Background II-16
Prognosis II-17
Stages of HD II-17
Symptoms and Signs II-18
Physical Symptoms II-18
Emotional Symptoms II-19
Mental Symptoms II-19
Genetics of Huntington's Disease II-20
Inheritance II-20
Mechanism II-21
Functions of HTT II-21
Effects of mHTT on Cells II-21
Macroscopic Effects of mHTT II-22
Diagnosis of HD II-22
Clinical Diagnosis II-23
Embryonic Diagnosis II-23
Differential Diagnosis II-23
Diagnostic Tests for Huntington's Disease II-24
Confirmatory Diagnostic Test II-24
Pre-symptomatic Diagnostic Test II-24
Prenatal Diagnostic Test II-24
Treatment Options II-24
Nutrition and Eating II-24
Social Activity II-25
Speech Therapy II-25
Physical Therapy II-25
Occupational Therapy II-25
Medication II-26
3. PRODUCT INTRODUCTIONS/CLINICAL TRIALS II-27
Suven Life Sciences Secures Two Patents in the US II-27
Medivation and Pfizer Begin Phase III Trial of Dimebon II-27
Alnylam and Medtronic Present New Preclinical Data on ALN-HTT II-27
NeuroSearch Presents ACR16 as Novel Huntington's Disease Therapy II-28
Raptor Pharmaceuticals Receives FDA Orphan Drug Designation
for Cysteamine II-29
NeuroSearch Receives Approval from EMEA for Huntexil(TM)as New
Brand Name for Pridopidine II-29
KeyNeurotek Pharmaceuticals Elucidates on Molecular
Pathomechanism of Huntingtin's Mutation II-30
NeuroSearch Begins Critical Phase III Program with ACR16 II-30
Avicena Proceeds to NIH Sponsored Phase III Trial for HD-02 II-31
EnVivo Pharmaceuticals Progresses on Major HDACi Program II-31
NeuroSearch Files CTA in Europe to Begin Clinical Phase III
Program with ACR16 II-32
4. RECENT INDUSTRY ACTIVITY II-33
Alliance Pharma to Acquire Cambridge Laboratories II-33
Alliance Pharma Concludes Distribution Deal With Biovail II-33
Lundbeck Acquires LifeHealth II-33
Lundbeck Acquires Ovation II-33
Biovail Purchases Global Rights for Tetrabenazine from Cambridge II-33
Raptor Pharmaceuticals, TorreyPines Concluded Merger II-34
Cambridge Laboratories Enters into New Agreements for
Marketing Xenazine® in North America II-34
CHDI Foundation Inks Agreement with AMRI for Drug Discovery II-34
Phytopharm Inks Agreement with CHDI Foundation to Evaluate Cogane II-35
NeuroSearch Repurchases Global Rights to ACR16 II-35
Raptor Pharmaceuticals Enters into Collaboration with Centre
Hospitalier Universitaire d'Angers for Phase II Clinical
Trial II-35
Targeted Genetics Acquires Full Rights from Sirna Therapeutics
to siRNA Development Program II-36
Cambridge Laboratories Receives Marketing Approval for
Tetrabenazine from Agencia Espanola de Medicamentos y
Productos Sanitarios II-36
Cambridge Laboratories Inks and Renews Agreements with Taiwan,
New Zealand, Finland and Australia II-37
CHDI Inked Collaboration Agreements with Galapagos II-37
Biovail Acquires Prestwick Pharmaceuticals II-37
Ovation Pharmaceuticals Acquires License to Commercialize
Xenazine® in the US II-38
Aegera Therapeutics Inks License Agreement with Neurologix II-38
Intellect Neurosciences Inks Agreement with CHDI Foundation to
Evaluate Potential of OXIGON(TM) II-39
Pipex Pharmaceuticals Entered into CRADA with Veterans
Affairs Medical Center for Evaluation of COPREXA II-39
5. FOCUS ON SELECT PLAYERS II-40
Alnylam Pharmaceuticals, Inc. (USA) II-40
Amarin Corporation, Plc (Ireland) II-40
Avicena Group, Inc. (USA) II-40
Biovail Corporation (Canada) II-40
Ceregene, Inc. (USA) II-41
Cortex Pharmaceuticals, Inc. (USA) II-41
H. Lundbeck A/S (Denmark) II-41
Intellect Neurosciences Incorporation (USA) II-42
Medivation, Inc (USA) II-42
NeuroSearch A/S (Denmark) II-42
Prana Biotechnology Limited (Australia) II-43
Raptor Pharmaceuticals Corp. (USA) II-43
Targeted Genetics Corporation (USA) II-43
Trophos SA (France) II-44
Vertex Pharmaceuticals Incorporated (USA) II-44
6. GLOBAL MARKET PERSPECTIVE II-45
Table 1: Global Current and Future Analysis for Huntington's
Disease Therapeutics with Annual Revenue Figures in US$
Million for Years 2009 through 2015 (includes corresponding
Graph/Chart) II-45
III. COMPETITIVE LANDSCAPE
Total Companies Profiled: 37
------------------------------------------
Region/Country Players
------------------------------------------
The United States 19
Canada 3
Japan 1
Europe 12
France 1
Germany 1
The United Kingdom 2
Italy 1
Rest of Europe 7
Asia-Pacific (Excluding Japan) 2
------------------------------------------
To order this report:
Pharmaceutical Industry:
More Market Research Report
Check our Company Profile, SWOT and Revenue Analysis!
Contact: Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
